<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FILGRASTIM</span><br/>(fil-gras'tim)<br/><span class="topboxtradename">Neupogen<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">hematopoietic growth factor</span><br/><b>Prototype: </b>Epoetin alfa<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Endogenous G-CSF regulates the
         production of neutrophils within the bone marrow; not species specific and primarily affects neutrophil proliferation, differentiation
         and selected end-cell functional activity (including enhanced phagocytic activity, antibody-dependent killing, and the increased
         expression of some functions associated with cell-surface antigens).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases neutrophil proliferation and differentiation within the bone marrow.</p>
<h1><a name="uses">Uses</a></h1>
<p>To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving
         myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; to decrease neutropenia
         associated with bone marrow transplant; to treat chronic neutropenia; to mobilize peripheral blood stem cells (PBSCs) for
         autologous transplantation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to <i>Escherichia coli</i>derived proteins, simultaneous administration with chemotherapy, and myeloid cancers.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neutropenia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 5 mcg/kg/d by 30 min infusion, may increase by 5 mcg/kg/d (max: 30 mcg/kg/d) <span class="rdroute">SC</span> 5 mcg/kg/d as single dose, may increase by 5 mcg/kg/d (max: 20 mcg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Subcutaneous &amp; Intravenous</span><ul>
<li>Do not administer filgrastim 24 h before or after cytotoxic chemotherapy.</li>
<li>Use only one dose per vial; do not reenter the vial.</li>
<li>Prior to injection, filgrastim may be allowed to reach room temperature for a maximum of 6 h. Discard any vial left at room
                     temperature for &gt;6 h.
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent/</span><span class="methodtype">Continuous:</span> May dilute with 1050 mL D5W to yield 15 mcg/mL or greater. If more diluent is used to yield concentrations of 515
                  mcg/mL, 2 mL of 5% human albumin must be added for each 50 mL D5W (prior to adding filgrastim) to prevent adsorption to
                  plastic IV infusion materials.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give a single dose over 1530 min.   <span class="methodtype">Continuous:</span> Give a single dose over 424 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span> <b> Amphotericin B,</b> <b>cefepime,</b> <b>cefoperazone,</b> <b>cefotaxime,</b> <b>cefoxitin,</b> <b>ceftizoxime,</b> <b>ceftriaxone,</b> <b>cefuroxime,</b> <b>clindamycin,</b> <b>dactinomycin,</b> <b>etoposide,</b> <b>fluorouracil,</b> <b>furosemide,</b> <b>gentamicin,</b> <b>heparin,</b> <b>imipenem,</b> <b>mannitol,</b> <b>methylprednisolone,</b> <b>metronidazole,</b> <b>mitomycin,</b> <b>piperacillin,</b> <b>prochlorperazine,</b> <b>thiotepa.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store refrigerated at 2°8° C (36°46° F). Do not freeze. Avoid shaking.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Abnormal ST segment depression. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">GI:</span> Nausea, anorexia. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Bone pain,</span> hyperuricemia, <span class="speceff-common">fever.</span>
<h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Elevations in <b>leukocyte alkaline phosphatase,</b> <b>serum alkaline phosphatase,</b> <b>lactate dehydrogenase,</b> and <b>uric acid</b> have been reported. These elevations appear to be related to increased bone marrow activity.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Can interfere with activity of <span class="classification">cytotoxic agents</span>, do not use 24 h before or after <span class="classification">cytotoxic agents</span>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from SC site. <span class="typehead">Onset:</span> 4 h. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Elimination:</span> Probably excreted in urine. <span class="typehead">Half-Life:</span> 1.47.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain a baseline CBC with differential and platelet count prior to administering drug. Obtain CBC twice weekly
            during therapy to monitor neutrophil count and leukocytosis. Monitor Hct and platelet count regularly.
         </li>
<li>Discontinue filgrastim if absolute neutrophil count exceeds 10,000/mm<sup>3</sup> after the chemotherapy-induced nadir. Neutrophil counts should then return to normal.
         </li>
<li>Monitor patients with preexisting cardiac conditions closely. MI and arrhythmias have been associated with a small percent
            of patients receiving filgrastim.
         </li>
<li>Monitor temperature q4h. Incidence of infection should be reduced after administration of filgrastim.</li>
<li>Assess degree of bone pain if present. Consult physician if nonnarcotic analgesics do not provide relief.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report bone pain and, if necessary, to request analgesics to control pain.</li>
<li> 							Note: Proper drug administration and disposal is important. A puncture-resistant container for the disposal of used syringes and
            needles should be available to the patient. 						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>